Literature DB >> 14999395

[Prevention of deep vein thrombosis in surgical departments].

S Haas1.   

Abstract

Prophylactic treatment against deep vein thrombosis has become a routine part of surgical treatment. The indications and the form of prophylaxis selected depend on the patient's individual risk profile, which is determined in turn by a combination of exposing and predisposing risk factors. The exposing risk factors depend on the type of surgery and trauma the patient is exposed to, while the predisposing risks are determined by factors peculiar to the patient. This review deals with the modalities of prophylaxis currently available, pharmacological details relating to these, and their clinical significance. In addition, evidence-based data, recommendations for the duration of prophylaxis derived from official guidelines, and medicolegal aspects are discussed. The development of new anticoagulants is expanding the range of prophylactic methods, which means further information is needed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999395     DOI: 10.1007/s00104-004-0854-4

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  16 in total

Review 1.  Prevention of venous thromboembolism.

Authors:  W H Geerts; J A Heit; G P Clagett; G F Pineo; C W Colwell; F A Anderson; H B Wheeler
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

2.  Late occurring clinical deep vein thrombosis in joint-operated patients.

Authors:  O E Dahl; T E Gudmundsen; L Haukeland
Journal:  Acta Orthop Scand       Date:  2000-02

3.  Thromboembolism after foot and ankle surgery. A multicenter study.

Authors:  M S Mizel; H T Temple; J D Michelson; R G Alvarez; T O Clanton; C C Frey; A P Gegenheimer; S R Hurwitz; L D Lutter; M G Mankey; R A Mann; R A Miller; E G Richardson; L C Schon; F M Thompson; M L Yodlowski
Journal:  Clin Orthop Relat Res       Date:  1998-03       Impact factor: 4.176

Review 4.  Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.

Authors:  J Hirsh; T E Warkentin; S G Shaughnessy; S S Anand; J L Halperin; R Raschke; C Granger; E M Ohman; J E Dalen
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

Review 5.  Extended prophylaxis against venous thromboembolism following total hip and knee replacement.

Authors:  R D Hull; G F Pineo
Journal:  Haemostasis       Date:  1999-12

6.  The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.

Authors:  T E Warkentin; L J Elavathil; C P Hayward; M A Johnston; J I Russett; J G Kelton
Journal:  Ann Intern Med       Date:  1997-11-01       Impact factor: 25.391

7.  Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.

Authors:  Bengt I Eriksson; Giancarlo Agnelli; Alexander T Cohen; Ola E Dahl; Patrick Mouret; Nadia Rosencher; Christina Eskilson; Ingela Nylander; Lars Frison; Mats Ogren
Journal:  Thromb Haemost       Date:  2003-02       Impact factor: 5.249

8.  Mutation in blood coagulation factor V associated with resistance to activated protein C.

Authors:  R M Bertina; B P Koeleman; T Koster; F R Rosendaal; R J Dirven; H de Ronde; P A van der Velden; P H Reitsma
Journal:  Nature       Date:  1994-05-05       Impact factor: 49.962

Review 9.  The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review.

Authors:  David Gustafsson; Margareta Elg
Journal:  Thromb Res       Date:  2003-07-15       Impact factor: 3.944

10.  Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.

Authors:  Alexander G G Turpie; Kenneth A Bauer; Bengt I Eriksson; Michael R Lassen
Journal:  Arch Intern Med       Date:  2002-09-09
View more
  2 in total

1.  [Prophylaxis of thromboembolic events in surgery. DVT prophylaxis: a comparison of out-patient and hospitalized patients].

Authors:  K Fecher; W Ewald; A Fürst; V Hohmann; P Bramlage
Journal:  Unfallchirurg       Date:  2013-03       Impact factor: 1.000

2.  [Compliance of patients undergoing thromboprophylaxis with enoxaparin: the COMFORT study].

Authors:  S Rübenacker; J Kaiser; M Guschmann
Journal:  Chirurg       Date:  2013-03       Impact factor: 0.955

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.